Browse our 1,000+ Publications​

Latest Publications

Three‑year follow‑up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL‑3

Izutsu K, et al.
International Journal of Hematology
January 2026
Authors and Affiliates
Koji Izutsu1  · Daigo Akahane2  · Tomomi Toubai3  · Toko Saito4  · Yuko Mishima5  · Tomoaki Fujisaki6  · Momoko Nishikori7  · Takahiro Kumode8  · Youko Suehiro9  · Kenji Ishitsuka10 · Poliana Patah11 · Ami Takahashi12 · Barbara D’Angelo Månsson13 · Elena Favaro13 · Noriko Fukuhara14 1 Department of Hematology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan 2 Department of Hematology, Tokyo Medical University, Tokyo, Japan 3 Department of Internal Medicine III, Division of Hematology and Cell Therapy, Faculty of Medicine, Yamagata University, Yamagata, Japan 4 Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan 5 Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 6 Department of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan 7 Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 8 Department of Hematology and Rheumatology, Kindai University, Osaka, Japan 9 Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan 10 Department of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan 11 AbbVie, North Chicago, IL, USA 12 Genmab, Tokyo, Japan 13 Genmab, Copenhagen, Denmark 14 Department of Hematology, Tohoku University, Sendai, Japan

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Foster L, et al.
Blood Cancer Journal
January 2026
Authors and Affiliates
Laahn Foster 1✉, Larry D. Anderson Jr 2 , Alfred Chung3 , Chakra P. Chaulagain 4 , Erin Pettijohn5 , Andrew J. Cowan6 , Caitlin Costello7 , Sarah Larson8 , Douglas W. Sborov 9 , Kenneth H. Shain10, Rebecca Silbermann11, Peter Voorhees 12, Maria Krevvata13, Huiling Pei14, Sharmila Patel15, Vipin Khare15, Annelore Cortoos15, Robin Carson13, Thomas S. Lin15 and Ashraf Badros16 1 Division of Hematology Oncology, University of Virginia, Charlottesville, VA, USA. 2 Myeloma, Waldenstrom’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. 3 Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 4 Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, FL, USA. 5 Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA. 6 Division of Medical Oncology, Fred Hutch Cancer Center/University of Washington, Seattle, WA, USA. 7 Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 8 Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 9 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 10Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 11Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 12Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. 13Johnson & Johnson, Spring House, PA, USA. 14Johnson & Johnson, Titusville, NJ, USA. 15Johnson & Johnson, Horsham, PA, USA. 16Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Einsele H, et al.
Lancet Oncology
January 2026
Authors and Affiliates
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen,Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh,Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schecter, Nikoletta Lendvai,Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh PopatUniversitätsklinikumWürzburg, Medizinische Klinikund Poliklinik II, Würzburg,Germany (Prof H Einsele MD);Cancer Center ClinicaUniversidad de Navarra, CIMA,IDISNA, Pamplona, Spain(Prof J San-Miguel MD PhD);Medical College of Wisconsin,Milwaukee, WI, USA(Prof B Dhakal MD); Serviced’Hématologie, CHU HotelDieu, Nantes, France(Prof C Touzeau MD); CRCINA,INSERM, CNRS, Universitéd’Angers, Université de Nantes,Nantes, France (Prof C Touzeau);Site de Recherche Intégrée surle Cancer (SIRIC), ILIAD, INCA-DGOS-Inserm_12558, Nantes,France (Prof C Touzeau); Serviced’Hématologie et ThérapieCellulaire, Hôpital La Milétrie(Prof X Leleu MD PhD), andCentre d’Investigation CliniqueINSERM 1402 (Prof X Leleu),Poitiers University Hospital,Poitiers, France; AmsterdamUniversity Medical Center, VrijeUniversiteit Amsterdam,Amsterdam, Netherlands(Prof N W C J van de Donk MD PhD);Stanford University School ofMedicine, Stanford, CA, USA(Prof S Sidana MD); InstitutCatalà d’Oncologia(A Oriol MD PhD), and InstitutJosep Carreras (A Oriol),Hospital Germans Trias i Pujol,Badalona, Spain; Tel-AvivSourasky (Ichilov) MedicalCenter, Gray Faculty of Medicaland Health Sciences, Tel AvivUniversity, Tel Aviv, Israel(Prof Y C Cohen MD); PeterMacCallum Cancer Centre,Melbourne and RoyalMelbourne Hospital, Melbourne, VIC, Australia(Prof S J Harrison MBBS PhD);Translation Laboratory, Centreof Excellence in CellularImmunotherapy, PeterMacCallum Cancer Centre,Melbourne, VIC, Australia(Prof S J Harrison); Sir PeterMacCallum Department ofOncology, University ofMelbourne, Parkville, VIC,Australia (Prof S J Harrison);University Hospital ofSalamanca–IBSAL–CIC–CIBERONC, Salamanca, Spain(Prof M-V Mateos MD PhD);Hospital 12 de Octubre,Complutense University CNIO,MIC, Madrid, Spain(Prof J Martínez-López MD PhD);Fondazione IRCCS IstitutoNazionale dei Tumori Milano,University of Milano, Milan,Italy (Prof P Corradini MD);Centre Hospitalier Lyon Sud,Pierre-Bénite, France(L Karlin MD); Johnson &Johnson, Shanghai, China(D Chen MS); Johnson &Johnson, Apex, NC, USA(Q Li MS); Johnson & Johnson,Raritan, NJ, USA (T-m Yeh MS,A Ghosh MD PhD,J M Schecter MD,N Lendvai MD PhD); Johnson &Johnson, Spring House, PA,USA (K Li MS, V Plaks LLB PhD);Johnson & Johnson, Zug,Switzerland (A Slaughter PhD);Johnson & Johnson, BuenosAires, Argentina(C Lonardi PharmD); Johnson &Johnson, Beerse, Belgium(N Benachour MS); Johnson &Johnson, Neuss, Germany(M Vogel MD PhD); LegendBiotech USA, Somerset, NJ,USA (M Koneru MD PhD,N Patel BM BCh,E Florendo MSN); Royal PrinceAlfred Hospital, Sydney, NSW,Australia(Prof P J Ho MBBS DPhil);University of Sydney, Sydney,NSW, Australia (Prof P J Ho);University College LondonHospitals, NHS FoundationTrust, London, UK(R Popat MD PhD)

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial

Strati P, et al.
Nature Cancer
January 2026
Authors and Affiliates
Paolo Strati 1 , Lori Leslie2, Parveen Shiraz 3, Lihua E. Budde 4,Olalekan O. Oluwole5, Matthew Ulrickson 6, Aravind Ramakrishnan7,Teresa Zhang8, Jennifer Sun8, Francesca Milletti8, Justyna Kanska8, Rhine Shen8,Frank Neumann8, Hairong Xu8 & Krish Patel9 1Department of Lymphoma and Myeloma and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center,Houston, TX, USA. 2Indolent Lymphoma and CLL Research Programs, John Theurer Cancer Center, Hackensack, NJ, USA. 3Division of Blood and MarrowTransplantation and Cellular Therapy, Stanford University, Stanford, CA, USA. 4Department of Hematology and Hematopoietic Cell Transplantation,City of Hope National Medical Center, Duarte, CA, USA. 5Division of Hematology Oncology, Vanderbilt University Cancer Center, Nashville, TN, USA.6Section of Hematology, Stem Cell Transplant, and Cellular Therapy, Banner MD Anderson Cancer Center, Gilbert, AZ, USA. 7Center for Blood Cancersand Oncology, Texas Transplant Physician Group, Austin, TX, USA. 8Kite, a Gilead Company, Santa Monica, CA, USA. 9Lymphoma Program andHematologic Malignancies and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, USA

Venetoclax-Dexamethasone VersusPomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

Popat R, et al.
Journal of Clinical Oncology
December 2025
Authors and Affiliates
Rakesh Popat, MD, PhD1 ; Meral Beksac, MD2 ; Meletios A. Dimopoulos, MD3,4 ; Moshe E. Gatt, MD5 ; Francesca Gay, MD6 ;Jae-Cheol Jo, MD, PhD7 ; Prashant Kapoor, MD8 ; Eirini Katodritou, MD, PhD9 ; K. Martin Kort¨um, MD10 ; Silvia Ling, PhD, MBBS11 ;Chandramouli Nagarajan, MD12 ; Kenshi Suzuki, MD, PhD13; Lugui Qiu, MD14; Maika Onishi, MD15; Grace Ku, MD15 ; Monique Dail, PhD15 ;Nabanita Mukherjee, PhD16; Jeremy A. Ross, PhD16; Mohamed Ali Badawi, PhD16; Mary Jean Fusco, MD16; Edyta Dobkowska, MD17;Emma Arriola, PhD18; Orlando F. Bueno, MD, PhD16; Nizar J. Bahlis, MD19 ; Shinsuke Iida, MD20 ; Philippe Moreau, MD21; Jason Valent, MD22; andMar´ıa-Victoria Mateos, MD, PhD231Haematology Department, University College London Hospitals NHSFoundation Trust, London, United Kingdom2Department of Hematology, Ankara University, Ankara, Turkey3Department of Clinical Therapeutics, School of Medicine, National andKapodistrian University of Athens, Athens, Greece4Department of Medicine, Korea University, Seoul, South Korea5Department of Hematology, Hadassah Hebrew University MedicalCenter, Jerusalem, Israel6Division of Hematology 1, Department of Biotechnology and HealthScience, Azienda Ospedaliero-Universitaria Citt `a della Salute e dellaScienza, University of Torino, Torino, Italy7Department of Hematology and Oncology, Ulsan University Hospital,University of Ulsan College of Medicine, Ulsan, Korea8Division of Hematology, Mayo Clinic, Rochester, MN9Department of Hematology, Theagenion Cancer Hospital, Thessaloniki,Greece 10Department of Internal Medicine II, W¨urzburg University Hospital,University of W¨urzburg, W¨urzburg, Germany11Department of Haematology, Liverpool Hospital, Sydney, NSW,Australia12Department of Haematology, Singapore General Hospital, Singapore,Singapore13Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,Tokyo, Japan14National Clinical Research Center for Hematological Disorders & StateKey Laboratory of Experimental Hematology, Institute of Hematologyand Blood Diseases Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Tianjin, China15Genentech Inc, South San Francisco, CA16AbbVie Inc, North Chicago, IL17Pharmacyclics Switzerland GmbH, An AbbVie Company,Schaffhausen, Switzerland18AbbVie, Maidenhead, United Kingdom19Arnie Charbonneau Cancer Institute, University of Calgary, Calgary,AB, Canada20Department of Hematology and Oncology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japan21Department of Hematology, University Hospital Hˆotel-Dieu, Nantes,France22Department of Hematology and Medical Oncology, Cleveland ClinicFoundation, Taussig Cancer Institute, Cleveland, OH23Haematology Department, University Hospital of Salamanca, Institutode Investigaci ´on Biom´edica de Salamanca and Institute of CancerMolecular and Cellular Biology and CIBERONC, Salamanca, Spain

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Costa L, et al.
N Engl J Med
December 2025
Authors and Affiliates
Luciano J. Costa, M.D.,1 Nizar J. Bahlis, M.D.,2 Aurore Perrot, M.D., Ph.D.,3 Ajay K. Nooka, M.D., M.P.H.,4 Jin Lu, M.D.,5 Charlotte Pawlyn, M.B., B.Chir., Ph.D.,6,7 Roberto Mina, M.D.,8 Gaston Caeiro, M.D.,9 Alain Kentos, M.D.,10 Vania Hungria, M.D., Ph.D.,11 Donna Reece, M.D.,12 Ting Niu, M.D.,13 Anne K. Mylin, M.D., Ph.D.,14 Charlotte T. Hansen, Ph.D.,15 Raphael Teipel, M.D.,16 Britta Besemer, M.D.,17 Meletios A. Dimopoulos, M.D.,18,19 Elena Zamagni, M.D.,20,21 Satoshi Yoshihara, M.D.,22 Kihyun Kim, M.D.,23 Chang Ki Min, M.D.,24 Paul Geerts, M.D., Ph.D.,25 Elena Van Leeuwen-Segarceanu, M.D., Ph.D.,26 Agata Tyczynska, M.D., Ph.D.,27 Juan Luis Reguera, Ph.D.,28 Magnus Johansson, M.D.,29 Markus Hansson, M.D., Ph.D.,30 Mehmet Turgut, M.D.,31 Mark Grey, M.D.,32 Surbhi Sidana, M.D.,33 Paula Rodriguez-Otero, M.D., Ph.D.,34 Joaquin Martinez-Lopez, M.D., Ph.D.,35 Hamza Hashmi, M.D.,36 Robin Carson, M.D.,37 Rachel Kobos, M.D.,38 Weili Sun, M.D., Ph.D.,39 Kristen Lantz, Ph.D.,37 Anne Seifert, Ph.D.,40 Deborah Briseno-Toomey, M.S.N.,41 Lisa O’Rourke, M.S.N.,37 Maria Rubin, Ph.D.,38 Diego Vieyra, Ph.D.,37 Lijuan Kang, Ph.D.,39 and Maria Victoria Mateos, M.D., Ph.D.42 1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham; 2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; 3 Universite de Toulouse, Centre Hospitalier Universitaire, Service d’Hematologie, Institut Universitaire du Cancer de Toulouse– Oncopole, Cancer Research Center of Toulouse, Toulouse, France; 4Emory University, Winship Cancer Institute, Atlanta; 5Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing; 6Royal Marsden NHS Foundation Trust, London; 7 Institute of Cancer Research, London; 8Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy; 9Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina; 10Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium; 11Clinica São Germano, São Paulo; 12Princess Margaret Cancer Centre, Toronto; 13Department of Hematology, West China Hospital, Sichuan University, Chengdu; 14Department of Hematology, Rigshospitalet, Copenhagen; 15Department of Hematology, Odense University Hospital, Odense, Denmark; 16Medizinische Klinik und Poliklinik I Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany; 17Department of Internal Medicine II, University Tübingen, Tübingen, Germany; 18Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens; 19Department of Medicine, Korea University, Seoul, South Korea; 20 IRCCS Azienda Ospedaliero– Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy; 21Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy; 22Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan; 23Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; 24Department of Hematology, College of Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, South Korea; 25Department of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands; 26Department of Hematology, St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands; 27Department of Hematology and Transplantology, Medical University of Gdansk; Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland; 28Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de l of Hematology, Ondokuz Mayis University, Samsun, Turkey; 32 Lancashire Haematology Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Victoria Hospital, Blackpool, United Kingdom; 33 Stanford University School of Medicine, Palo Alto, CA; 34Cancer Center Clínica Universidad de Navarra, Pamplona, Spain; 35Hematology Department, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, Centro de Investigación Biomédica en Red de Cáncer, Madrid; 36Memorial Sloan Kettering Cancer Center, New York; 37 Johnson & Johnson, Spring House, PA; 38 Johnson & Johnson, Raritan, NJ; 39 Johnson & Johnson, Los Angeles; 40 Johnson & Johnson, High Wycombe, United Kingdom; 41 Johnson & Johnson, Yorba Linda, CA; 42Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain.

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Falchi L, et al.
Blood
November 2025
Authors and Affiliates
Lorenzo Falchi,1 Anna Sureda,2 Sirpa Leppä,3 Joost S. P. Vermaat,4 Marcel Nijland,5 Jacob Haaber Christensen,6 Sven de Vos,7 Harald Holte,8 Reid W. Merryman,9 Pieternella J. Lugtenburg,10, * Pau Abrisqueta,11 Kim M. Linton,12 Gauri Sunkersett,13 Daniela Hoehn,14 Ali Rana,14 Aqeel Abbas,14 Jennifer Marek,14 Yi Hao,14 Andrew J. Steele,14 Christopher Morehouse,14 Martin Hutchings,15 and David Belada16 1 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 2 Clinical Hematology Department, Institut Catala` d’Oncologia, L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 3 Department of Oncology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; 4 Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; 5 Department of Hematology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; 6 Department of Haematology, Odense University Hospital, Odense, Denmark; 7 Department of Medicine, Hematology/Oncology, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA; 8 Department of Oncology, Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway; 9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 10Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; 11Department of Hematology, Hospital Universitario Vall d’Hebron, Barcelona, Spain; 12Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom; 13AbbVie, North Chicago, IL; 14Genmab, Plainsboro, NJ; 15Department of Haematology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; and 164th Department of Internal Medicine, Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralové, ´ Czech Republic

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in theLINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Lee H, et al.
Clinical Lymphoma Myeloma & Leukemia
November 2025
Authors and Affiliates
Hans C. Lee,1 Jeffrey A. Zonder,2 Madhav V. Dhodapkar,3 Sundar Jagannath,4 James E. Hoffman,5 Attaya Suvannasankha,6 Mansi R. Shah,7 Suzanne Lentzsch,8 Rachid Baz,9 Joseph J. Maly,10 Swathi Namburi,11 Matthew J. Pianko,12 Jing Christine Ye,1 Ka Lung Wu,13 Rebecca Silbermann,14 Chang-Ki Min,15 Marie-Christiane Vekemans,16 Markus Munder,17 Ja Min Byun,18 Joaquín Martínez-Lopez,19 Michelle DeVeaux,20 Tito Roccia,20 Dhruti Chokshi,20 Megan Seraphin,20 Kate Knorr,20 Anita Boyapati,20 Anasuya Hazra,20 Karen Rodriguez Lorenc,20 Glenn S. Kroog,20 Naresh Bumma,21 Joshua Richter4 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Karmanos Cancer Institute, Detroit, MI 3Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 4Icahn School of Medicine at Mount Sinai, New York, NY 5Department of Medicine, University of Miami Health System, Miami, FL 6Department of Medicine, Indiana University Simon Cancer Center and Richard L. Roudebush VAMC, Indianapolis, IN 7Department of Medicine, Rutgers Cancer Institute, New Brunswick, NJ 8Columbia University Irving Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA 12Department of Internal Medicine, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Hematology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, Universitätsmedizin Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea 19Hospital Universitario 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc., Tarrytown, NY 21Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Previous Next